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Abstract 
Radiotherapy is a novel, non-invasive cancer treatment. Radioactive hollow microspheres, i.e., microcapsules, are 
attractive for in situ cancer radiotherapy because they can effectively reach tumors without settling in blood vessels. In 
particular, microcapsules 20-30 µm in size are expected to exhibit not only a radiotherapy effect but also embolization 
that blocks the nutrient supply to cancer cells. -ray irradiation is the most suitable source for in situ radiotherapy 
because of its moderate range. Several kinds of -emitting yttria (Y2O3) microcapsules have therefore been developed. 
Yttrium phosphate (YPO4) should have a longer irradiation effect than that of Y2O3 because the half-life of 
31P (14.3 
days) is longer than that of 90Y (64.1 hours). However, the preparation of YPO4 microcapsules has not been reported to 
date. In the present study, YPO4 microcapsules were fabricated using a water/oil (W/O) emulsion prepared by first 
dispersing a YPO4 sol into toluene containing a surfactant, with mechanical homogenization. The emulsion was then 
added into butanol to dehydrate the water phase and precipitate microcapsules. These were then heat-treated to improve 
their mechanical strength and chemical stability. Microcapsule fragility at low YPO4 sol concentrations in the water 
phase was attributed to the thinness of the microcapsule shell. The size of the microcapsules decreased with increasing 
emulsification speed. The chemical stability of the prepared microcapsules is similar to those of previously reported 
YPO4 and Y2O3 microspheres in weakly acidic conditions. Thus, little leakage of radioactive species into nearby 
healthy tissues is expected. The obtained microcapsules are expected to be highly effective for cancer radiotherapy. 
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1. Introduction 
Cancer has recently become the main cause of death in 
Japan [1]. Therefore, the development of efficient cancer 
treatments is urgently needed. Surgical excision is widely 
chosen as a treatment course. However, some organs do not 
recover their functions after surgery. The development of a 
non-invasive cancer treatment is needed to improve quality of 
life. 
Radiotherapy is a non-invasive cancer treatment but it is 
difficult to treat deep-seated cancer with low side effects by 
irradiation from outside the body. Recently, novel 
radiotherapies using ceramic microspheres imparting -ray 
irradiation have been developed [2]. As an irradiation source, a 
-emitter is liable to penetrate into the surrounding healthy 
tissues and consequently induce side effects, while an 
-emitter can convert another surrounding element into a 
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-emitter. Therefore, a -emitter, which has an average range of 
2.5 mm, is suitable for in situ radiotherapy. Implanted 
microspheres reach tumors through blood vessels and can thus 
locally irradiate a deep-seated tumor. Hollow microspheres 
(microcapsules) are expected to effectively reach tumors 
without settling in blood vessels, unlike dense microspheres. In 
particular, those with a size of about 20-30 µm can shut off the 
supply of nutrients to cancer cells by embolization [2]. In 
addition, they are attractive as carriers of anti-cancer agents in 
drug delivery. 
It is known that non-radioactive 89Y, with a natural 
abundance of 100%, can be converted into β-emitting 90Y, 
whose half-life is 64.1 hours, by neutron bombardment [3]. 
Based on this, microspheres composed of Y2O3-Al2O3-SiO2 
glass [4-6], Y2O3 ceramics [7-10], and 
90Y-containing resin 
[11] have been proposed. However, the half-life of 90Y is 
somewhat brief for effective radiotherapy. Non-radioactive 31P, 
with a natural abundance of 100%, can be converted into 
β-emitting 32P, whose half-life is 14.3 days, by neutron 
bombardment. Therefore, yttrium phosphate (YPO4) is 
expected to possess a longer irradiation effect in vivo than that 
of Y2O3. Although the preparation of dense YPO4 microspheres 
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has previously been reported [7,12], that of YPO4 
microcapsules has not. 
In the present study, YPO4 microcapsules were prepared 
via the precipitation of YPO4 from a water/oil (W/O) emulsion 
and subsequent heat treatment. To evaluate the optimal 
conditions for the preparation of YPO4 microcapsules suitable 
for radiotherapy, the effects of YPO4 concentration in the water 
phase and emulsification speed on the shape and diameter of 
the particles were investigated. In addition, the chemical 
stability of the microcapsules was evaluated in a simulated 
body environment. 
2. Materials and methods 
NaOH and 1-butanol were purchased from Nacalai Tesque 
Inc. (Kyoto, Japan). Other reagents were purchased from Wako 
Pure Chemical Industries (Osaka, Japan). 80 mL of 0.56 M 
Y(CH3COO)3 and 20 mL of 2.3 M KH2PO4 aqueous solutions 
were mixed. The resulting precipitates were collected by a 
centrifugal separator (CN-2060, As-one Co., Osaka, Japan) and 
washed with ultrapure water. They were then dispersed in 15 or 
30 mL of 0.1 M HNO3 and stirred at room temperature for 24 h 
to obtain a YPO4 sol. 5 mL of the sol were then mixed with 
50 mL of toluene containing nonionic surfactant (Span80) at 
0.5 mass% and emulsified at various speeds, ranging from 2000 
to 3000 rpm, for 10 min using a rotary homogenizer (Homo 
Mixer Mark II, Tokushu Kika Co., Osaka, Japan). The resultant 
W/O emulsion was immediately added to 150 mL of 1-butanol 
and stirred for 1 min. The precipitates were filtered and dried at 
60 °C for 24 h, heated to 1000 °C at a rate of 5 °C/min, and 
kept at that temperature for 2 h. 
The microstructure of the powder product was 
characterized by X-ray diffraction (XRD; MXP3V, Mac 
Science Ltd., Japan), scanning electron microscopy (SEM; 
S-3500N, Hitachi Co., Japan), and an energy-dispersive X-ray 
analyser (EDX; Model EX-400; Horiba Co., Kyoto, Japan). 
The particle size distribution was characterized by measuring 
the size of each particle from SEM images. The chemical 
stability of the microcapsules was examined as follows. 50 mg 
of microcapsules were kept in 20 mL of 50 mM 2- 
(N-morpholino) ethanesulfonic acid (MES) buffer for 10 days 
at 36 °C under vigorous stirring. The pH of the MES solution 
was buffered at 6 by the dropwise addition of 1 M NaOH 
because the pH around tumors is reported to be sometimes 
weakly acidic through the secretion of lactic acid [13]. Y and P 
concentrations released from the microcapsules into the buffer 
were measured by inductively coupled plasma (Optima 
4300DV Cyclon, Perkin-Elmer Co., England) atomic emission 
spectroscopy (ICP-AES). The fractions of Y and P released 
from the microcapsules were calculated using the following 
equation: 
  
Released fraction =
Molar quantity of Y or P released from the sample into MES (mol)
Total molar quantity of Y or P contained in the sample (mol)
 
                                                ( 1 ) 
 
3. Results 
Figure 1 shows SEM images of the non-heated particles 
prepared from YPO4 sol mixed with either 15 or 30 mL of 
HNO3 solution. Microspheres with good spherical shapes were 
obtained in the former, while almost all of the particles were 
broken in the latter. A YPO4 sol containing 15 mL of HNO3 
solution was used for subsequent sample preparation. Figure 2 
shows SEM images and the size distribution of the particles 
obtained at various emulsification speeds after heat treatment at 
1000 °C. The particle sizes ranged from 5 to 50 µm, and tended 
to decrease with increasing emulsification speed. Figure 3 
shows a SEM image of cross-sections of the particles after heat 
treatment at 1000 °C. The obtained microspheres were found to 
have a hollow structure. Figure 4 shows XRD patterns of the 
microcapsules after heat treatment at 1000°C. The sample was 
amorphous before heat treatment (Data not shown), while 
peaks assigned to crystalline tetragonal xenotime-type YPO4 
(JCPDS card no. 11-0254) were observed after heat treatment. 
The crystallinity of the samples increased with increasing heat 
treatment temperature (Data not shown). Fractions of Y and P 
released from the microcapsules into MES buffer during 
stability tests were 1.4 × 10-5 and 6.6 × 10-4, respectively. Y/P 
molar ratios of the microcapsules before and after soaking in 
MES buffer were 1.27 ± 0.07 and 1.54 ± 0.18, respectively 
(n = 5). 
 
Figure 1. SEM images of non-heated particles prepared from a YPO4 
sol mixed with 15 or 30 mL of HNO3 solution (emulsification 
speed of 3000 rpm). 
 
Figure 2. SEM images and size distribution of particles fabricated at 
various emulsification speeds after heat treatment at 1000 °C. 
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Figure 3. SEM image of cross-sections of particles after heat treatment 
at 1000 °C (emulsification speed of 2000 rpm). 
 
Figure 4. XRD patterns of microcapsules after heat treatment at 1000°C 
(emulsification speed 2000 rpm). 
4. Discussion 
It was determined that YPO4 microcapsules can be 
efficiently obtained using a W/O emulsion. During this process, 
microcapsule formation is thought to progress as follows [14]. 
YPO4 sol is dispersed as a water phase in toluene to form the 
W/O emulsion. The sol is dehydrated by diffusion of 1-butanol 
from the oil phase to the water phase. A YPO4 gel then 
precipitates at the W/O interface because it is sparingly soluble 
in 1-butanol. Consequently, the shell of the YPO4 microcapsule 
is created. When the volume of HNO3 solution in the water 
phase is too high, the resulting particles are too brittle to 
maintain a spherical shape (see Fig. 1). The mechanical 
strength of the microcapsules is low because a very thin shell 
forms at low YPO4 concentration. A similar relationship 
between precursor concentration and wall thickness was 
reported for silica microcapsules [15]. 
The microcapsule size decreased with increasing 
emulsification speed. The droplet size of the water phase in the 
W/O emulsion generally decreases with increasing rotation 
speed because of increased shear stress [16]. It is assumed that 
the droplet size of the water phase strongly governs the size of 
the microcapsules produced. The relative frequency of particle 
sizes suitable for radiotherapy (20-30 µm) was the highest at an 
emulsification speed of 2000 rpm (See Fig. 2). 
The release fraction of Y of the present microcapsules was 
similar to that from dense YPO4 microspheres obtained by heat 
treatment of gel spheres at 1100 °C [12], and much lower than 
that from dense YPO4 microspheres created by plasma melting 
and subsequent quenching [7]. For the latter, Kawashita et al. 
found that acid-soluble impurities accumulated at the grain 
boundary of the microspheres, causing low chemical stability 
[7]. The present results support the view that normal heat 
treatment is more suitable than quenching for the fabrication of 
microspheres with high chemical stability. 
The released fraction of P was 47 times higher than that of 
Y, as shown in Table 1. This means that the Y/P molar ratio of 
the released chemical species differed from that of the original 
YPO4 microspheres, which had a molar ratio of about one 
[7,12]. It has been reported that AlPO4·1.5H2O dissolves 
unevenly, releasing a larger amount of P than Al in weakly 
acidic conditions of around pH 6, because the released Al3+ is 
hydrated and re-precipitated in this pH region [17]. A similar 
phenomenon may occur in the case of the present YPO4 
microcapsules. The increase in the Y/P molar ratio of the 
microcapsules after soaking in MES buffer supports this 
assumption (see Table 2). 
Table 1. Fractions of Y and P released from samples into MES buffer at 
pH 6 at 36 °C for 10 days (emulsification speed of 2000 rpm). 
Y P 
1.4 × 10-5 6.6 × 10-4 
 
Table 2. Y/P molar ratios of microcapsules before and after soaking in 
MES buffer at pH 6 at 36 °C for 10 days (emulsification speed 
of 2000 rpm, n = 5). 
Before After 
1.27 ± 0.07 1.54 ± 0.18 
5. Conclusion 
YPO4 microcapsules with diameters in the range of 
20-30 µm were obtained by a wet process in a W/O emulsion. 
The size of the microcapsules can be controlled well by the 
emulsification speed. The chemical stability of the 
microcapsules in buffer solutions was as high as those 
previously reported for YPO4 microspheres. These 
microcapsules are expected to be useful for the in situ 
radiotherapy treatment of cancer. 
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